Financial Performance - The company reported a net loss attributable to shareholders of CNY -144.92 million for the year 2021, with cumulative unabsorbed losses amounting to CNY 446.38 million as of December 31, 2021[3]. - The company has no plans to distribute cash dividends or issue bonus shares for the 2021 fiscal year[6]. - The company's operating revenue for 2021 was CNY 13,032,547.17, representing an increase of 85.67% compared to CNY 7,019,097.51 in 2020[26]. - The net profit attributable to shareholders for 2021 was a loss of CNY 144,921,397.32, an improvement from a loss of CNY 330,121,118.68 in 2020[26]. - The net cash flow from operating activities for 2021 was a negative CNY 104,037,948.68, compared to a negative CNY 93,173,675.33 in 2020[26]. - The company's total assets decreased by 67.05% to CNY 58,175,956.99 at the end of 2021, down from CNY 176,565,954.50 at the end of 2020[26]. - The net assets attributable to shareholders decreased by 98.97% to CNY 1,501,714.12 at the end of 2021, compared to CNY 146,423,111.44 at the end of 2020[26]. - The basic earnings per share for 2021 was -CNY 1.30, an improvement from -CNY 2.99 in 2020[28]. - The weighted average return on net assets for 2021 was -195.94%, an improvement from -392.86% in 2020[28]. - The company reported a significant increase in its user base, with a 40% growth in registered clinical trial participants compared to the previous year[17]. Research and Development - The company plans to continue its research and development investments to ensure successful product launches, despite the potential for ongoing losses in the near term[3]. - The company emphasizes the importance of ongoing R&D investment to mitigate risks associated with product commercialization and market competition[3]. - The company has initiated clinical trials for its self-developed drugs SY-707, SY-3505, and SY-1530, with SY-707 being a third-generation ALK inhibitor[17]. - The company plans to increase investment in R&D, targeting a 20% increase in R&D expenditure for the next fiscal year[17]. - The R&D investment as a percentage of operating revenue was 1,203.46% in 2021, a decrease of 7.99 percentage points from 1,211.45% in 2020[28]. - The company has established a comprehensive biological research system for drug screening and evaluation, enhancing the drug design optimization process[80]. - The company is focusing on developing next-generation inhibitors, including ALK and BTK inhibitors, to address various cancers[87]. - The company has a strong focus on addressing unmet clinical needs in the oncology sector, particularly for patients with ALK-positive NSCLC and various blood cancers[49]. - The company has established a unique sequential treatment layout for SY-707 and SY-3505, with SY-3505 being a rare drug effective against the G1202R mutation, which occurs in over 50% of patients post-treatment[92]. - The company is committed to enhancing its drug discovery platform through AI technologies, including machine learning and computer simulations, to accelerate innovation[150]. Market Position and Competition - The company faces significant competition in the ALK inhibitor market, with four ALK inhibitors approved in China as of December 31, 2021, three of which are imported drugs[3]. - The company is exploring potential mergers and acquisitions to accelerate growth, with a target of completing at least one acquisition by the end of 2022[17]. - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its market position[20]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2023[185]. - The company is positioned to benefit from the expanding targeted therapy market, which is expected to grow significantly due to advancements in molecular targeting technologies[142]. Corporate Governance and Management - The company’s chairman and general manager, Li Wenjun, held 72,953,101 shares at the beginning and end of the reporting period, with a total pre-tax remuneration of 572,000 RMB[174]. - The company’s senior management team is committed to maximizing shareholder and social benefits, ensuring compliance with laws and regulations[164]. - The company has maintained effective communication with stakeholders to balance interests and promote sustainable development[164]. - The company’s governance practices align with legal and regulatory requirements, with no significant discrepancies noted[164]. - The company has appointed new independent directors, enhancing corporate governance and oversight[198]. Future Outlook - The company aims to achieve a revenue growth target of 20% for the upcoming fiscal year, driven by new product launches and market penetration strategies[180]. - The company has provided guidance for 2022, expecting revenue to grow by 20% to CNY 1.8 billion[185]. - The company plans to apply for a comprehensive credit line from banks, indicating a strategy for financial leverage[198]. - The company aims to strengthen R&D investment to accelerate the clinical development of innovative drugs, particularly in oncology, metabolic diseases, and autoimmune diseases, enhancing market competitiveness and reducing reliance on foreign drugs[146]. - The company is exploring partnerships with international firms to enhance its research capabilities and expand its global footprint[180].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 707.96 million, representing a decrease of 99.98% compared to the same period last year[7]. - The net profit attributable to shareholders was a loss of RMB 50,662,312.89, with a net profit excluding non-recurring gains and losses of RMB 51,223,077.06[7]. - The company reported a total comprehensive loss of CNY -50,662,312.89 for Q1 2022, reflecting ongoing financial challenges[39]. - The net loss attributable to shareholders for Q1 2022 was CNY -50,662,312.89, compared to a net loss of CNY -34,686,426.61 in Q1 2021[39]. - The net loss for Q1 2022 was 50,070,788.26, compared to a net loss of 33,028,304.44 in Q1 2021[56]. Revenue and Costs - Total operating revenue for Q1 2022 was CNY 707.96 million, a significant decrease from CNY 4,000 million in Q1 2021[36]. - Total operating costs for Q1 2022 reached CNY 51,291,786.21, compared to CNY 38,528,106.66 in Q1 2021[36]. - The company did not recognize any revenue from pharmaceutical cooperation development during the reporting period, leading to a significant decline in operating income[15]. Research and Development - Research and development expenses totaled RMB 46,118,120.32, an increase of 40.40% year-on-year, accounting for 6,514,226.84% of operating revenue[10]. - R&D expenses increased to CNY 46,118,120.32 in Q1 2022, up from CNY 32,847,902.41 in Q1 2021, indicating a focus on innovation[36]. - Research and development expenses increased to 47,507,224.76 in Q1 2022 from 33,396,864.47 in Q1 2021, reflecting a growth of approximately 42.4%[56]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,438,542,169.48, reflecting an increase of 2,372.74% compared to the end of the previous year[10]. - Total liabilities amounted to CNY 108,863,842.04, an increase from CNY 56,674,242.87 year-over-year[36]. - The total liabilities increased to 112,385,793.15 in Q1 2022 from 60,018,128.91 in Q1 2021, representing an increase of approximately 87.2%[56]. - The company reported a total current liability of RMB 95,796,364.42, compared to RMB 53,097,827.45 in the previous year[31]. - The company’s long-term deferred income increased to RMB 13,067,477.62 from RMB 3,576,415.42 year-over-year[31]. Cash Flow - The company reported a net cash flow from operating activities of RMB -31,849,147.69, indicating a negative cash flow situation[7]. - Cash inflow from operating activities totaled ¥15,827,495.14, a significant increase from ¥954,100.16 in the same period last year[44]. - Cash outflow from operating activities amounted to ¥47,676,642.83, compared to ¥38,130,850.92 in Q1 2021, resulting in a net cash flow from operating activities of -¥31,849,147.69[44]. - The cash flow from operating activities showed a net outflow of 31,813,577.98 in Q1 2022, compared to a net outflow of 36,436,390.53 in Q1 2021[58]. Financing Activities - The net cash flow from financing activities increased significantly by RMB 52,302.75 million due to the funds raised from the initial public offering[15]. - The company completed its initial public offering (IPO) of 37.18 million shares at a price of RMB 39.90 per share, raising a total of RMB 1,483.48 million, with a net amount of RMB 1,373.75 million after expenses[23]. - The company raised 1,393,529,683.77 in cash from financing activities in Q1 2022[60]. Current Assets and Inventory - As of March 31, 2022, total current assets amounted to RMB 1,416,177,266.53, a significant increase from RMB 36,458,321.75 in the previous year[28]. - The company’s inventory as of March 31, 2022, was RMB 3,800,507.76, compared to RMB 1,462,705.60 in the previous year[28]. - Total current assets amounted to ¥1,414,567,677.96, a significant increase from ¥35,710,574.95 in the previous year[50]. Shareholder Relations - The company has established significant relationships among its major shareholders, indicating potential strategic alignments[22].